Imugene, a clinical-stage immuno-oncology company, is celebrating more than two years of “complete response” for one of its bile duct cancer trial participants in its CF33-MAST-VAXINIA trial.
Imugene, a clinical-stage immuno-oncology company, is celebrating more than two years of “complete response” for one of its bile duct cancer trial participants in its CF33-MAST-VAXINIA trial.